Reviewing Inhibrx Biosciences (NASDAQ:INBX) & Voyager Therapeutics (NASDAQ:VYGR)

Voyager Therapeutics (NASDAQ:VYGR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Valuation and Earnings

This table compares Voyager Therapeutics and Inhibrx Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37 million	2.81	-$119.72 million	($1.73)	-1.05
Inhibrx Biosciences	$1.30 million	1,025.98	-$140.05 million	($8.88)	-10.20

Voyager Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Voyager Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 4.03, meaning that its stock price is 303% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Voyager Therapeutics and Inhibrx Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1	0	1	1	2.67
Inhibrx Biosciences	1	2	2	1	2.50

Voyager Therapeutics currently has a consensus target price of $25.00, suggesting a potential upside of 1,269.86%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 117.97%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Voyager Therapeutics is more favorable than Inhibrx Biosciences.

Institutional and Insider Ownership

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Voyager Therapeutics and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-416.32%	-63.42%	-49.40%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Summary

Voyager Therapeutics beats Inhibrx Biosciences on 7 of the 13 factors compared between the two stocks.

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system. Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system.

About Inhibrx Biosciences

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company’s oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.